Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUoENDE: Durvalumab + Chemotherapy Followed by Durvalumab + Olaparib in pMMR Advanced/Recurrent Endometrial Cancer
NCT06746116Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Nov 2028
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of durvalumab and olaparib in endometrial cancer (EC), sponsored by AstraZeneca. Primary endpoint: Number of patients with Adverse Events. Started Dec 2024; status: active, not recruiting.
02
Drugs
durvalumabolaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06746116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746116.